HomePLX • NYSEAMERICAN
add
Protalix Biotherapeutics Inc
Previous close
$2.23
Day range
$2.11 - $2.24
Year range
$1.32 - $3.19
Market cap
172.42M USD
Avg Volume
1.46M
P/E ratio
46.35
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 9.12M | -49.93% |
Operating expense | -9.73M | -85.01% |
Net income | -5.50M | -184.76% |
Net profit margin | -60.34 | -269.26% |
Earnings per share | — | — |
EBITDA | -4.27M | -156.62% |
Effective tax rate | -15.24% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 30.27M | -13.08% |
Total assets | 82.35M | 12.16% |
Total liabilities | 34.12M | 12.94% |
Total equity | 48.23M | — |
Shares outstanding | 80.57M | — |
Price to book | 3.72 | — |
Return on assets | -14.15% | — |
Return on capital | -19.80% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -5.50M | -184.76% |
Cash from operations | 2.03M | -49.14% |
Cash from investing | -1.11M | 92.74% |
Cash from financing | 146.00K | -95.97% |
Net change in cash | 1.03M | 113.51% |
Free cash flow | 2.88M | 72.67% |
About
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. Wikipedia
CEO
Founded
1993
Headquarters
Website
Employees
226
